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http://dx.doi.org/10.1016/j.pedneo.2
1875-9572/Copyright ª 2015, TaiwanAsparaginase is one of the most important chemotherapeutic agents against pediatric acute
lymphoblastic leukemia (ALL), the most common form of childhood cancer. The therapeutic
efficacy (e.g., chemoresistance) and adverse effects of asparaginase (e.g., hypersensivity
and pancreatitis) have been investigated over the past four decades. It was suggested early
on that leukemic cells are resistant to asparaginase because of their increased asparagine syn-
thetase activity. Afterward, other mechanisms associated with asparaginase resistance were
reported. Not only leukemic cells but also patients themselves may play a role in causing as-
paraginase resistance, which has been associated with unfavorable outcome in children with
ALL. This article will briefly review asparaginase therapy in children with ALL and comprehen-
sively analyze recent reports on the potential mechanisms of asparaginase resistance.
Copyright ª 2015, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Acute lymphoblastic leukemia (ALL) is the most common
cancer in children. An estimated 6000 new cases of ALL are
diagnosed yearly in the United States; roughly 60% of cases
occur in people aged younger than 20 years.1 Recent ad-
vances in intensive chemotherapy, as well as adequate
supportive care, have made significant improvements in
childhood ALL, so that approximately 80% of the children
are cured (Table 1).2e11 According to the registry of themh.org.tw.
014.10.006
Pediatric Association. Published bTaiwan Childhood Cancer Foundation, there are about
130e140 newly diagnosed ALL children (younger than
18 years), accounting for 25% of all childhood cancers in
Taiwan. The treatment of childhood ALL in Taiwan has
improved during the past decade. Overall survival improved
significantly from 75.5% in 1997e2001 to 83.5% in
2002e2007.10 The high cure rate for ALL is attributable to
the improved supportive care, more precise risk stratifica-
tion, and personalized chemotherapy based on the char-
acteristics of leukemic cells and hosts.12
Asparaginase is an enzyme isolated from various natural
sources. However, only Escherichia coli and Erwinia chrys-
anthemi asparaginase are currently available for medicaly Elsevier Taiwan LLC. All rights reserved.
Table 1 Results of selected clinical trials for pediatric acute lymphoblastic leukemia.
Study Years of study No. of
patients
Age
range (y)
Event-free survival
at 5 y (%)
Overall survival
at 5 y (%)
Reference
BFM-95 1995e1999 2169 0e18 79.6  0.9 87.0  0.7 Mo¨ricke et al3
COG 2000e2005 7153 0e21 NA 90.4  0.5 Hunger et al2
DCOG-9 1997e2004 859 1e18 80.6  1.4 86.4  1.2 Veerman et al4
DFCI 00-01 2000e2004 492 0e18 80.0  2.0 91.0  1.0 Vrooman et al5
JCCLSG ALL 2000 2000e2004 305 1e15 79.7  2.4 89.2  1.8 Yamaji et al6
Ma-Spore ALL 2003 2002e2011 556 0e18 80.6  3.5 89.2  2.7 Yeoh et al7
MRC UKALL 2003 2003e2011 3126 1e25 87.2  14 91.5  1.2 Vora et al8
NOPHO-2000 2002e2007 1023 1e15 79.4  1.5 89.1  11 Schmiegelow et al9
TPOG-2002 2002e2007 788 0e18 77.4  1.7 83.5  1.6 Liang et al10
SJCH XV 2000e2007 498 1e18 85.6  2.9 93.5  1.9 Pui et al11
Note. From “Biology, risk stratification, and therapy of pediatric acute leukemias: an update,” by C.H. Pui, W.L. Carroll, S. Meshinchi,
R.J. Arceci, 2011, J Clin Oncol, 29, p. 551e65. ª 2011 American Society of Clinical Oncology. Adapted with permission.52.
BFMZ BerlineFrankfurteMu¨nster; COGZ Children’s Oncology Group; DCOGZ Dutch Children’s Oncology Group; DFCIZ DanaeFarber
Cancer Institute Consortium; JCCLSGZ Japanese Children’s Cancer and Leukemia Study Group; Ma-Spore Z MalaysiaeSingapore; MRC
UKALL Z Medical Research Council United Kingdom Acute Lymphoblastic Leukemia; NA Z not available; NOPHOZ Nordic Society of
Pediatric Hematology and Oncology; TPOG Z Taiwan Pediatric Oncology Group; SJCRHZ St. Jude Children’s Research Hospital.
288 S.-H. Chenuse. Polyethylene glycol (PEG)easparaginase is a conjugate
of the native E. coli asparaginase covalently linked to PEG
at sites not affecting enzymatic activity. The characteris-
tics of various asparaginase preparations are summarized in
Table 2. Asparaginase has been highly successful for
inducing remissions in acute leukemia since 1967.13 Aspar-
aginase exerts its antileukemic activity by converting aspar-
agine to aspartic acid in the extracellular fluid.14 Most normal
cells can synthesize asparagine, but leukemic lymphoblasts
are sensitive to the depletion of extracellular asparagine,
putatively because they express low levels of asparagine
synthetase (ASNS)15e17 or they lack the ability to upregulate
the expression of ASNS when exposed to asparaginase.18,19
The relative inability of leukemic lymphoblasts to produce
their own asparagine to compensate for the shortage of
extracellular asparagine reduces asparagine-dependent
protein synthesis, resulting in leukemic cell death.20
Extensive clinical data support the benefit of intensive
asparaginase treatment compared with less intensiveTable 2 Main characteristics of various asparaginase preparatio
Native Escherichia coli
asparaginase
Trade name Elspar
Leunase
Kidrolase
Crasnitin
Asparaginase medac
FDA approval 1978
Half-life (d)47,53,54 1.08 e 1.35 (IM)
Route IV, IM
Estimated equivalent doses
for complete asparagine
depletion for 2 wk
6000e10,000 U/m2
every 2e3 d
Frequency of antiasparaginase
antibody formation55e59
20e42%
FDAZ Food and Drug Administration; IM Z intramuscular; IV Z intraregimens in pediatric ALL.21e23 Resistance to asparaginase
has been demonstrated to be an unfavorable prognostic
factor.24e27 One may reasonably postulate that resistant
leukemic cells would have accesses to increase their aspara-
gine in sufficientquantity tomeet their needs. In recent years,
considerable effort has been made to address fundamental
questions about the role of ASNS in asparaginase resistance.
However, data from some recent studies on the importance of
ASNS are conflicting (Table 3). In addition to the leukemic
cells, there is increasing evidence of host factors that can
affect asparaginase resistance. In thisarticle, themechanisms
contributing to asparaginase resistance will be reviewed.1.1. Baseline high ASNS expression level in
leukemic cells
Horowitz et al15 reported experiments on the ASNS activity
of several transplanted mouse leukemias. Seven differentns.
Erwinia chrysanthemi
asparaginase
Pegylated form of native
E. coli asparaginase
Erwinase Oncospar
2011 1994
0.27 (IV)
0.65 (IM)
5.5 e 5.7 (IM)
IV, IM IV, IM
20,000e25,000 U/m2
every 2e3 d
2500e3500 U/m2 every 2 wk
8e33% 2e11%
venous.
Table 3 Summary of recent studies with conflicting conclusions on the impact of asparagine synthesis on asparaginase sensitivity in leukemic cells.
Sample origin Specific cell lines/ALL subtypes Sample
No.
Methods to determine
ASNS activity
Relationship between
ASNS and ASP sensitivity
The comparison of ASNS level
in one subtype to other subtypes
Reference
NCI60 cancer cell lines * 6 Microarray ASNS[, GI50[ Scherf et al
28
Primary ALL TEL/AML1 and non-TEL/AML1 ALL 47 qRT-PCR No correlation TEL ALL > non-TEL ALL Stams et al32
Primary ALL TEL/AML1 ALL 30 qRT-PCR No correlation Stams et al32
Primary ALL Non-TEL/AML1 ALL 17 qRT-PCR No correlation Stams et al32
Primary ALL Non-TEL/AML1 ALL 117 qRT-PCR and microarray ASNS[, LC50[ Stams et al
34
Leukemic cell lines y 16 Microarray ASNS[, LC50[ Fine et al
30
Primary ALL 38 Microarray No correlation Fine et al30
Primary ALL 173 Microarray ASNS[, LC50[ Holleman et al
29
Primary ALL TEL ALL
Non-TEL/AML1 ALL
20
23
qRT-PCR Not mentioned TEL ALL > non-TEL ALL Krejci et al33
Primary ALL TEL/AML1 ALL
Non-TEL/AML1 ALL
57
231
Microarray Not mentioned TEL ALL < non-TEL ALL Iwamoto et al35
Primary ALL Hyperdiploid ALL
Nonhyperdiploid ALL
51
237
Microarray Not mentioned Hyperdiploid ALL <
nonhyperdiploid ALL
Iwamoto et al35
Primary ALL T-ALL
B-lineage ALL
47
241
Microarray Not mentioned T-ALL > B-lineage ALL Iwamoto et al35
Leukemic cell lines Jurkat, SUP T1 2 qRT-PCR ASNS[, EC50[ Estes et al
60
Leukemic cell lines MOLT-4, Nalm6, REH 3 qRT-PCR No consistent correlation Su et al36
Leukemic cell lines MOLT-4, Nalm6, REH 3 Immunoblotting ASNS[, IC50[ Su et al
36
Note. From “A genome-wide approach identifies that the aspartate metabolism pathway contributes to asparaginase sensitivity,” by S.H. Chen, W Yang, Y Fan, G Stocco, K.R. Crews, J.J.
Yang, et al., 2011, Leukemia, 25, p. 66e74.44 ª2011 Macmillan Publishers Ltd.
ALL Z acute lymphoblastic leukemia; ASNS Z asparagine synthetase; ASP Z asparaginase; EC50 Z effective concentration leading to 50% cell death; GI50 Z concentration with 50%
growth inhibition of cells; IC50 Z concentration with 50% inhibition to cell growth; LC50 Z concentration lethal to 50% of cells.
* MOLT4, CEM, HL-60 (TB), SR, RPMI-8226, K562.
y Nalm20, Nalm21, Nalm29, Nalm30, SUP-B15, HB, RS411, BV173, HAL, UOC, MV, Nalm27, Nalm6, REH, 697, RCH-ACV.
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290 S.-H. Chenasparaginase-sensitive mouse leukemias proved to have no
or only slight ASNS activity. In contrast, asparaginase-
resistant leukemias showed appreciable ASNS activity.
Haskell and Canellos16 studied the ASNS levels in 18 leu-
kemia patients who were subsequently treated with
asparaginase. They found that the ASNS in leukemic cells
was nearly undetectable prior to therapy regardless of
subsequent response to asparaginase treatment, although
the ASNS level in the asparaginase-resistant group was
slightly higher than in the asparaginase-sensitive group.
Kiriyama et al17 later showed that asparaginase-sensitive
human leukemic cell lines exhibited a lower baseline
ASNS level than asparaginase-nonsensitive ones. ASNS was
also reported as one of the top genes with at least 2-fold
expression level in two resistant T-ALL cell lines at
different maturation stages.17
Gene expression profiling studies by microarray analysis
revealed conflicting results. Scherf et al28 showed that six
leukemic cell lines had very high negative correlation be-
tween the ASNS expression and asparaginase sensitivity.
Holleman et al29 found that ASNS was one of the genes
discriminating asparaginase-sensitive and asparaginase-
resistant leukemic cells from newly diagnosed pediatric
ALL patients. Fine et al30 demonstrated that ASNSwas one of
the genes that had different asparaginase-sensitive and
asparaginase-resistant cell lines in accordance with previous
reports. However, baseline ASNS expression was not associ-
ated with asparaginase sensitivity in clinical ALL samples.
The t(12;21)þ ALL, which harbors the TEL/AML1 gene
fusion and accounts for about 25% of pediatric ALL, was
found to be significantly related to in vitro drug sensitivity
for asparaginase.31 The simple paradigmwould be sensitivity
to asparaginase in t(12;21)þ ALL emerged via a low baseline
expression of ASNS. Surprisingly, Stams et al32 showed that
the expression of ASNS in t(12;21)þ ALL was significantly
higher than in t(12;21) ALL. The ASNS expression did not
differ in sensitive and resistant t(12;21)þ ALL, either. The
same trend was also demonstrated by Krejci et al.33 Both
studies had only a small number of patient samples and used
real-time quantitative polymerase chain reaction (RTQ-PCR)
to determine ASNS mRNA expression. Although ASNS
expression was not linked to asparaginase resistance in
t(12;21)þ ALL, Stams et al34 later reported that the ASNS
expression determined by either RTQ-PCR or microarray
significantly differed between sensitive and resistant
t(12;21)þ ALL. With a larger sample size and microarray
analysis, a different resultwas shownby Iwamoto et al.35 The
ASNS expression levels were found to be significantly lower in
t(12;21)þ ALL compared to t(12;21) ALL.
Notably, the quantification of ASNS expression in
leukemic cells by mRNA is limited by the fact that the
relationship between the ASNS mRNA and intracellular
protein concentrations in primary ALL has not been estab-
lished. Su et al36 tested the correspondence between ASNS
mRNA expression by RTQ-PCR and ASNS protein content by
immunoblotting. Asparaginase resistance was estimated by
half-maximal inhibitory concentration (IC50) after exposure
to asparaginase. Their observations demonstrated that the
correlation between ASNS protein and IC50 was much better
than that between the IC50 and the ASNS mRNA content.
This may imply that measuring the ASNS protein rather than
mRNA can predict asparaginase resistance. More recently,Abbatiello et al37 developed a highly sensitive and selective
nanoflow reversed-phase liquid chromatography-tandem
mass spectrometry (RPLC-MS/MS) technique to quantify
ASNS protein levels. They successfully measured the ASNS
protein concentration directly in four patient blast sam-
ples. This new technique may help to reassess the corre-
lation between ASNS expression and asparaginase
resistance in the future.
In conclusion, a different sample size, determination of
gene expressions, and origin of sample may account for the
discrepancy in the results. However, these studies indicate
that the baseline ASNS level plays a role but is not the only
factor for leukemic cells’ resistance to asparaginase.
1.2. Upregulation of ASNS expression in leukemic
cells in asparagine-depleted environment
In nine leukemia patients with paired ASNS activity deter-
mination before and during/after asparaginase treatment,
the asparaginase-sensitive group showed no change in ASNS
with therapy; however, there was a 7-fold increase in the
mean level of ASNS levels in the asparaginase-resistant
group.16 The difference between the ASNS levels in the
sensitive and resistant groups, determined during/after
asparaginase treatment, was highly significant.
Hutson et al19 also demonstrated that resistance to
asparaginase in leukemic cell lines was mediated in vitro by
an upregulation of ASNS expression in response to aspara-
gine depletion of the culture medium. Aslanian et al18
further examined the reversibility of the upregulation of
ASNS caused by asparaginase treatment in asparaginase-
resistant leukemic cells. They found that the elevated
ASNS expression in the resistant cells was not fully reversed
even 6 weeks after asparaginase had been removed from
the culture medium.
However, asparaginase-sensitive leukemic cells were
later revealed also to upregulate ASNS after asparaginase
treatment. Stams et al32 exposed samples from t(12;21)þ
and t(12;21) ALL patients in vitro to asparaginase. Almost
all samples showed upregulation of ASNS, which was inde-
pendent from t(12;21) status and cellular sensitivity to
asparaginase. Appel et al38 also demonstrated that the
upregulation of ASNS occurred in both sensitive and resis-
tant cases within 24 hours of in vivo exposure to aspar-
aginase. These data imply that mechanisms other than
upregulated expression levels of ASNS contribute to cellular
asparaginase resistance.
1.3. Increased substrates for ASNS reaction in
leukemic cells
Aslanian and Kilberg39 found that multiple adaptive changes
affect the ASNS substrate availability in asparaginase-
resistant leukemic cell line. These changes appear to sup-
port increased asparagine biosynthesis by increasing the
intracellular levels of aspartateandglutamine.Asparaginase-
resistant cells produced more glutamine by an increase in
glutamine synthetase (GS) activity. These cells also enhanced
the uptake of extracellular glutamine via secondary active
Naþ-dependent transporters. However, there was little or
no aspartate uptake by these cells. Recently, Appel et al25
Asparaginase in acute lymphoblastic leukemia 291demonstrated that the levels of intracellular amino acids did
not significantly differ among different in vitro sensitivity
cases or in vivo clinical responders. Therefore, the contri-
bution of the ASNS substrate, aspartate, and glutamine’s
resistance to asparaginase remains unclear.
1.4. Influence on protein synthesis and apoptosis in
leukemic cells
Protein synthesis is fundamental in all living cells, both
benign and malignant. Amino acid deficiency impairs pro-
tein synthesis and leads to apoptosis and cell death. Many
tRNA syntheses and amino acid transporters were shown to
increase expression in human cells with amino acid star-
vation.30 In asparaginase-resistant ALL cells, several ribo-
somal protein genes were overexpressed, indicating the
possible role of protein synthesis in asparaginase resis-
tance.29 Holleman et al40 further analyzed the expression
patterns of 70 apoptosis genes and tested the association
between the expression of these genes and in vitro drug
resistance in B-lineage ALL cells. Of the 70 apoptosis genes,
three were associated with asparaginase resistance. Over-
expression of BCL2L13, one of the genes associated with
asparaginase resistance, was also associated with an unfa-
vorable clinical outcome.
2. Host factors
There is increasing interest in the host factors resulting in
asparaginase resistance of leukemic cells. Iwamoto et al35
described the protective effect of mesenchymal cells in
leukemic cells against asparaginase treatment in bone
marrow microenvironment. They showed that bone marrow
mesenchymal cells express significantly higher amounts of
ASNS than leukemic cells. They then showed that the
resistance of leukemic cell lines and some specimens of
primary leukemia to asparaginase correlated with the
expression of ASNS by mesenchymal cells. Forced increased
expression of ASNS by the mesenchymal cell leads to
increased resistance of the ALL cells; conversely, reduced
expression of ASNS by the mesenchymal cell leads to
enhanced sensitivity of the ALL cells.
The childhood obesity problem has become epidemic in
the United States and other industrialized countries. In vivo
and in vitro models have shown that obesity impairs the
efficacy of chemotherapeutics against ALL cells, likely
mediated by adipocytes.41 Ehsanipour et al42 examined
bone marrow biopsy specimens from four obese and four
lean adolescent leukemia patients for expression of ASNS
and GS. They found that the GS expression was markedly
increased in bone marrow adipocytes after induction
chemotherapy, whereas ASNS expression appeared to be
unaltered after treatment. They further cultured ALL cells
over fibroblasts or adipocytes in media with asparaginase.
They observed that adipocytes protected ALLs from aspar-
aginase treatment via release of glutamine, which com-
plemented the previous finding from Iwamoto et al.35 The
protective effect from such microenvironment is still open
to debate.
In recent years, pharmacogenetics/pharmacogenomics
in childhood ALL has become a major field of research. Thegenetic variation is a key determinant for the interindi-
vidual differences in treatment resistance. Luo et al43
identified that the single nucleotide polymorphism in the
promotor region of the ASNS gene, e92G>A, is associated
with increased ASNS expression and is more common in
pediatric leukemic patients than among normal control in-
dividuals. We used an agnostic genome-wide approach to
identify inherited genomic variants that contribute to
asparaginase resistance using normal lymphoblastoid cell
lines from 87 trio members of European ancestry and 54
primary ALL leukemic blast samples at diagnosis.44 We
found that the top-ranked pathway was that of aspartate
metabolism, which may be linked directly to the mecha-
nism of action of asparaginase. The two most highly ranked
genes (ADSL and DARS ) in this pathway encompassed seven
single nucleotide polymorphisms. Moreover, we found that
more sensitive ALL subtypes (hyperdiploid and TEL-AML1)
had lower ADSL expression than the more resistant sub-
types (T-ALL), which is consistent with higher ADSL
expression associated with resistance.
Because asparaginase is a foreign protein, hypersensi-
tivity reactions due to antiasparaginase antibody produc-
tion are common, occurring in up to 45% of patients.45 The
development of these antibodies appears to be more
commonly observed in native E. coli asparaginase than in
the pegylated enzyme.46 The development of anti-
asparaginase antibodies may shorten the half-life of
asparaginase, prevent or delay absorption after intramus-
cular injection of asparaginase, or interfere with aspar-
aginase activity.47e49 Therefore, it confers resistance to
asparaginase therapy and reduced therapeutic efficacy in
some clinical studies.50,51
3. Conclusion
The intensive administration of asparaginase improved the
treatment outcomes in children with ALL. It is crucial to
recognize the mechanisms for the development of both
in vitro and in vivo resistance by leukemic cells. The role of
the host factor is increasing. Adequate asparaginase expo-
sure may result in a lower clearance of steroids, which may
potentiate the cytotoxicity of vincristine. Therefore, it is
important for clinicians to choose the appropriate man-
agement in patients with asparaginase resistance. Switch-
ing to another preparation may be a difficult choice.
Measurement of asparaginase level during asparaginase
treatment may help to guide the decision of switching
preparations or dose escalation. Further studies should
continue investigating and promoting effective aspar-
aginase therapy individually.
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